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High and Interrelated Rates of PD-L1
Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
A. Marijne Heeren, Bas D. Koster, Sanne Samuels, Debbie M. Ferns, Dafni Chondronasiou, Gemma G. Kenter, Ekaterina S. Jordanova, and Tanja D. de Gruijl Synopsis: Heeren, Koster, and colleagues performed a comprehensive analysis of the immune-cell subsets and cytokine release profile in tumor-draining lymph nodes from patients with cervical cancer, providing information about the local immunosuppressive mechanisms that promote immune escape and metastatic spread.
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Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma Jun Zhou, Meghna Gupta, Xinqi Wu, Charles Yoon, Anita Giobbie-Hurder, and F. Stephen Hodi Synopsis: Zhou and colleagues identify broad immune responses to ATP6S1 in the peripheral blood of patients with advanced melanoma; augmented humoral responses from ipilimumab treatment correlated with beneficial clinical outcomes, and the authors propose the development of ATP6S1 as a biomarker and therapeutic target. 
ABOUT THE COVER
Parallels between tumors and wound healing have been recognized for more than a century and continue to intrigue. An integral property shared by both tumors and healing wounds is increased expression of vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF). Many types of cancer cells overexpress VEGF, as do parenchymal and inflammatory cells adjacent to sites of tissue injury, whether a cut finger, a stroke, or a myocardial infarct. Wherever it is expressed, VEGF initiates a chain of events that begins with increased vascular permeability to plasma and plasma proteins and is followed by activation of clotting and the laying down of a fibrin gel provisional stroma. Fibroblasts and new blood vessels infiltrate the fibrin stroma, transforming it into granulation tissue, and, ultimately, into dense fibrous connective tissue, called "scar tissue" in wounds and "desmoplasia" in cancer. The new blood vessels that form in tumors and wounds are of six distinctly different types and result from both angiogenesis and arterio-venogenesis. The first angiogenic vessels to form are called "mother" vessels (MV). MVs are large structures, lined only by a single layer of greatly thinned endothelial cells; they are the vessel type that leaks plasma and plasma proteins in both tumors and wounds. MVs derive from preexisting normal venules and capillaries by a three-step process: proteolytic degradation of vascular basement membranes, pericyte detachment, and 4-to 5-fold enlargement driven by intravascular hydrostatic pressure that is no longer opposed by the resistance of intact basement membranes and pericytes.
The cover is an H&E-stained section of a human ovarian carcinoma with three prominent MVs in the tumor stroma. The inset shows a fluorescent image of a rat skin wound at an early stage of healing, demonstrating several MVs that are leaking a circulating macromolecular tracer, FITCdextran. For details see the Masters of Immunology primer by Harold F. Dvorak on page 1 of this issue. CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org 
ABOUT THE MASTER
Harold Fisher Dvorak, MD, was the chief of pathology at the Beth Israel Deaconess Medical Center (BIDMC) and the Mallinckrodt Professor of Pathology at Harvard Medical School (HMS) from 1979 to 2005. He received the 2014 Canada Gairdner International Award for discovering vascular endothelial growth factor (VEGF), a protein that has been effectively targeted in cancer and wet macular degeneration. Dr. Dvorak is a superb classic scientist who enjoys research and pursues science diligently and elegantly. In the early 1970s, Dr. Dvorak and colleagues demonstrated that delayed-type hypersensitivity reactions are heterogeneous, involving various immune-cell populations, and are associated with increased vascular permeability to plasma proteins due to the secretion by macrophages and mast cells of a new factor, which they characterized as the vascular permeability factor (VPF, renamed VEGF).
In 1983, Dr. Dvorak and his colleagues were the first to demonstrate that tumor cells secreted VEGF. This seminal discovery provided the molecular basis for the field of angiogenesis. His research has helped elucidate the nature and composition of tumor stroma and the pathogenesis of its generation. Dr. Dvorak made the critical observation that tumors behave like "wounds that do not heal" in that the vascular and stromal responses they induce closely mimic those of healing wounds. In both settings, and also in chronic inflammatory reactions, the initial sequence of events includes vascular hyperpermeability resulting in plasma fibrinogen extravasation, extravascular fibrin deposition, induction of angiogenesis, and progression to desmoplasia or scar formation. Based on Dr. Dvorak's work and the work of others, VEGF is regarded as the key angiogenic factor contributing to the neovascularization associated with tumor growth and other adaptive or pathologic angiogenic responses. More recently, his work has characterized the different types of blood vessels that tumors generate and the molecular mechanisms by which they form.
Dr. Dvorak has published over 300 original papers and review articles. He is a fellow of the American Association for the Advancement of Science and of the National 
